Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H
Department of Medicine, Juntendo University School of Medicine, Tokyo, Japan.
J Am Soc Nephrol. 1995 Feb;5(8):1585-90. doi: 10.1681/ASN.V581585.
This study assessed glomerular endothelin (ET)-1, ET-3, and ET-receptor A and B mRNA levels in puromycin aminonucleoside (PAN)-induced nephrosis. During the nephrotic stage, 8 days after PAN injection, ET-1 and ETB receptor mRNA were elevated by 2.8 +/- 0.8-fold (P < 0.01) and 2.4 +/- 0.9-fold (P < 0.01), respectively, as compared with controls. These mRNA levels decreased to control levels by Day 20, when the nephrosis was in remission. In contrast, glomerular ETA receptor mRNA levels did not change in PAN nephrosis or control rats during the experimental period. ET-3 mRNA was not detected in the glomeruli of PAN nephrosis or control rats. Additionally, plasma ET concentration and glomerular ET production were measured in PAN nephrosis and control rats by radio-immunoassay. Eight days after PAN injection, ET-1 levels in plasma and glomeruli were not significantly altered in rats with PAN-induced nephrosis (glomeruli, 104.68 +/- 16.46 pg/mg of protein versus 98.24 +/- 13.68 pg/mg of protein; plasma, 2.68 +/- 1.10 versus 2.52 +/- 0.98 pg/mL). The administration of methylprednisolone to PAN rats resulted in the rapid disappearance of proteinuria and partially attenuated the increased ET-1 and ETB receptor gene expression in the glomeruli. These data indicate that glomerular ET-1 and ETB receptor expression in PAN nephrosis in increased at the mRNA level and that methylprednisolone treatment results in an attenuated increase.
本研究评估了嘌呤霉素氨基核苷(PAN)诱导的肾病中肾小球内皮素(ET)-1、ET-3以及ET-A和ET-B受体的mRNA水平。在肾病阶段,即PAN注射后8天,与对照组相比,ET-1和ETB受体mRNA分别升高了2.8±0.8倍(P<0.01)和2.4±0.9倍(P<0.01)。到第20天肾病缓解时,这些mRNA水平降至对照水平。相比之下,在实验期间,PAN肾病大鼠和对照大鼠的肾小球ETA受体mRNA水平没有变化。在PAN肾病大鼠和对照大鼠的肾小球中未检测到ET-3 mRNA。此外,通过放射免疫测定法测量了PAN肾病大鼠和对照大鼠的血浆ET浓度和肾小球ET生成。PAN注射后8天,PAN诱导的肾病大鼠的血浆和肾小球中的ET-1水平没有显著改变(肾小球:104.68±16.46 pg/mg蛋白质,对照为98.24±13.68 pg/mg蛋白质;血浆:2.68±1.10,对照为2.52±0.98 pg/mL)。给PAN大鼠施用甲基泼尼松龙导致蛋白尿迅速消失,并部分减弱了肾小球中ET-1和ETB受体基因表达的增加。这些数据表明,PAN肾病中肾小球ET-1和ETB受体的表达在mRNA水平上增加,并且甲基泼尼松龙治疗导致增加的程度减弱。